Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.75 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.75 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.75 |
| ▸ | CFTR | P13569 | 2/20 | 0.75 |
| ▸ | PDE2A | O00408 | 2/20 | 0.75 |
| ▸ | PDE1A | P54750 | 2/20 | 0.75 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.75 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | PDE5A | O76074 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | SCN1A | P35498 | 1/20 | 0.75 |
| ▸ | PDE6C | P51160 | 1/20 | 0.75 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.75 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isobutylmethylxanthine SCHEMBL50315 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCFTR | |
| Isobutylmethylxanthine SCHEMBL28814716 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCFTR | |
| Isobutylmethylxanthine SCHEMBL7637581 | 0.83 | PDE4A (0.94) | PDE4APDE4BPDE4CPDE4DCFTR | |
| Isobutylmethylxanthine SCHEMBL4262798 | 0.82 | PDE4A (0.92) | PDE4APDE4BPDE4CPDE4DCFTR | |
| SCHEMBL7096675 | 0.81 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DCFTR | |
| SCHEMBL239725 | 0.80 | CFTR (1.00) | PDE4APDE4BPDE4CPDE4DCFTR | |
| Isobutylmethylxanthine SCHEMBL3185038 | 0.78 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4DCFTR | |
| SCHEMBL10579248 | 0.77 | ADORA2B (1.00) | PDE4APDE4BPDE4CPDE4DCFTR | |
| SCHEMBL1376703 | 0.76 | ADORA2A (0.59) | PDE4APDE4BPDE4CPDE4DCFTR | |
| SCHEMBL1460828 | 0.76 | ADORA2A (0.59) | PDE4APDE4BPDE4CPDE4DCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | claimed |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2014-08-07 | — | — | US | claimed |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | claimed |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | claimed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| CN-100379737-C | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-04-09 | — | — | CN | claimed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | claimed |
| CN-1646531-A | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | CN | claimed |
| CN-113633641-A | MPO inhibitors for the treatment of huntington's disease and multiple system atrophy | 阿斯利康(瑞典)有限公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2021013942-A1 | USE OF MYELOPEROXIDASE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS SUFFERING FROM MYELOPROLIFERATIVE NEOPLASMS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-01-28 | — | — | WO | disclosed |
| US-20200405724-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2020-12-31 | — | — | US | disclosed |
| US-10772890-B2 | Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938 | ASTRAZENECA AB (SE) | 2020-09-15 | — | — | US | disclosed |
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | disclosed |
| US-7425560-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| CN-100379737-C | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-04-09 | — | — | CN | disclosed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | disclosed |
| CN-1646531-A | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | CN | disclosed |
| EP-1499613-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003089430-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772890-B2 | Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938 | MPO, CAT, SOD1 | PDE4A 483/4885PDE4B 835/4885PDE4C 784/4885 |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | PDE4A 814/4885PDE4B 1209/4885PDE4C 1293/4885 |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | MPO, XDH, EPX | PDE4A 793/4885PDE4B 958/4885PDE4C 1247/4885 |
| US-20200405724-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | MPO, CAT, HTT | PDE4A 548/4885PDE4B 977/4885PDE4C 835/4885 |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | PDE4A 814/4885PDE4B 1209/4885PDE4C 1293/4885 |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | MPO, XDH, EPX | PDE4A 793/4885PDE4B 958/4885PDE4C 1247/4885 |
| US-20090054468-A1 | New Use 938 | MPO, CAT, HTT | PDE4A 429/4885PDE4B 665/4885PDE4C 673/4885 |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | PDE4A 814/4885PDE4B 1209/4885PDE4C 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.